The graduate and post-graduate programs of the college are recognized by the Medical Council of India. The courses offered are also recognized by General Medical Council (UK), Sri Lanka Medical Council and WHO. The college has been recognized by the Royal College of Obstetricians and Gynaecologists, UK, for the award of MRCOG. After the formation of JSS University (Established under Section-3 of UGC Act), JSS Medical College became a constituent college of the JSS University (now JSS Academy of Higher Education and Research-JSSAHER) from the Academic year 2008-2009, which is among the country's top 5 and world's top 500 universities as per The Times Higher Education Ranking, 2019 which also ranked JSSAHER as India's most impactful university. JSS Academy of Higher Education and Research has grabbed the 93rd spot in the Clinical and Health category, in the World University Rankings 2022 by THE (Times Higher Education Rankings) for 1500~ Universities across the globe. JSS is the only one higher education institute from India has got a top slot, in the top 100, at 93rd position. JSSAHER has been accredited by NAAC with an A+ grade. The students of this college are from all corners of India as well as from abroad.Attached to one of the biggest hospitals in India, it is one of the first institutions in the country to establish a plastination museum. JSS Body Donation Camp is also one of the biggest body donation camps in India.It has been ranked as one of the top medical colleges by Careers 360 and Outlook. JSSAHER also has a QS 4 star rating along with Autonomous Status granted by MHRD on recommendations of UGC for maintaining high standards in medical education.
Despite the well-established efficacy of injectable insulin in achieving and maintaining optimal glycaemic control, its acceptance among people living with diabetes (PWD) in India remains disproportionately low. Delayed or inadequate insulin therapy often results in prolonged poor glycaemic control, increasing the risk of diabetes-related complications and contributing to a higher healthcare burden. This review aims to examine key barriers to the initiation and intensification of injectable insulin therapy in India and to explore strategies to address these challenges. A narrative review of the existing literature was conducted to identify barriers influencing the use of injectable insulin. Barriers were categorized into patient-related, healthcare provider (HCP)-related, and healthcare system–related factors. Multiple interrelated barriers were identified. Patient-related barriers include fear of injections, social stigma, and misconceptions regarding insulin therapy. HCP-related barriers involve clinical inertia and limited time for patient education, which delay insulin initiation and intensification. System-level barriers include challenges related to access, affordability, and resource constraints within the healthcare infrastructure. Emerging strategies to overcome these obstacles include structured patient education, focused HCP training, healthcare policy interventions, and innovations such as non-invasive insulin delivery systems. Overcoming barriers to injectable insulin therapy requires a comprehensive, multi-stakeholder approach. Integration of educational, clinical, policy, and technological strategies may improve insulin acceptance and optimize diabetes management outcomes in India.
OBJECTIVE: This study aims to identify early electrode migration after cochlear implant (CI) surgery using imaging, mapping, and postoperative auditory and speech scores in order to enhance the performance of the implant and its outcome. STUDY DESIGN: A prospective study involving the bilaterally profound hearing-impaired children who underwent cochlear implantation from January 2021 to February 2024. SETTING: Patients who attended the paediatric hearing clinic in a tertiary care hospital for follow-up after 6 months to 1 year were recruited. METHODS: After a minimum of 6 months of cochlear implantation surgery, a ‘modified Stenver’s view’ and a ‘cochlear view’ mastoid x-ray was done to determine the electrode position, insertion depth and degree of insertion and compared with the x-ray taken on post-operative day one. The electrode position was then correlated with electrically evoked compound action potential (ECAP), impedance, CAP-12 (Categories of auditory performance) score and speech intelligibility rating (SIR). RESULTS: Out of 35 patients who enrolled for the study, 3 patients were found to have electrode migration, of which one patient had poor speech and auditory outcome. The cochlear view was found to be superior to modified Stenver’s view. CONCLUSIONS: Electrode migration is a rare but not uncommon complication that may not be easily picked up with ECAP and impedance monitoring in the post-operative period, warranting regular imaging such as cochlear view x-ray that is fast, cheap and has low radiation exposure to children. It also gives good electrode visibility and can determine the electrode position, angular insertion depth and electrode migration.
Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare lung disorder characterized by autoantibodies against Granulocyte–Macrophage Colony-Stimulating Factor (GM-CSF). Whole-lung lavage is the conventional treatment, but it does not address the underlying pathophysiology. This systematic review and meta-analysis aims to further evaluate the effects of inhaled GM-CSF on gas exchange, oxygenation, and lung volume. We conducted a systematic review and meta-analysis following PRISMA guidelines. A literature search was performed across PubMed, Embase, and the Cochrane Library from inception to October 2025. Randomized Controlled Trials (RCTs) comparing inhaled GM-CSF to a control in adult patients with aPAP were included. The primary outcomes assessed pulmonary gas exchange, oxygenation, and lung volume, while exercise capacity and dyspnea levels were secondary outcomes. Statistical analyses were performed using Review Manager (RevMan) version 5.4.1 and R version 4.5.2, with heterogeneity assessed using I2 statistics. Four phase III RCTs comprising 402 patients (224 inhaled GM-CSF, 178 control) with ≥ 25 weeks of follow-up were included. Inhaled GM-CSF significantly enhanced DLCO
BACKGROUND:Oral and ocular medications are frequently used in the treatment of allergic rhinitis (AR). As part of the update of the Allergic Rhinitis and its Impact on Asthma (ARIA)-EAACI guidelines, this manuscript presents the ARIA-EAACI 2024-2025 recommendations for oral and ocular treatments. METHODS:The ARIA-EAACI 2024-2025 guideline panel issued recommendations following the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) evidence-to-decision framework. Several sources of evidence were used to inform panel judgements and recommendations, including systematic reviews, mHealth and pharmacovigilance data as well as a survey on costs. RESULTS:Eight guideline questions concerning oral treatments for AR and three questions concerning ocular treatments were addressed. These questions led to the recommendations. Overall, these questions concern the choice between different classes of medication. They also discuss the role of oral antihistamines (OAH), leukotriene receptor antagonists (LTRA), ocular antihistamines (OcAH) and ocular mast cell stabilisers. Four questions had not been previously evaluated in ARIA guidelines, while, for the other four, there was a change in the strength or directionality of the recommendations. Overall, these guidelines recommend using intranasal corticosteroids over OAH and using OAH over LTRA. Moreover, they suggest using OAH over OcAH and suggest being against adding LTRA to OAH. Finally, considerations for choosing between different individual OAHs are presented. CONCLUSION:This ARIA-EAACI 2024-2025 article supports patients, their caregivers and healthcare professionals in choosing oral and ocular treatments for AR. Decisions on treatment should consider the clinical variability of the disease, patients' values and the affordability of medications.
